Connect Biopharma drops as asthma candidate fails in mid-stage trial
Connect Biopharma NASDAQ:CNTB lost nearly 40% in premarket trading on Tuesday after announcing that its lead candidate, rademikibart, failed to reach the primary endpoint in a Phase 2 trial for patients with asthma.The global trial, designed to evaluate rademikibart as an add-on therapy for acute e…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.